Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company operates within the biotechnology and biopharmaceutical industries, with a specific emphasis on leveraging genetically modified viruses to stimulate systemic anti-tumor immune responses. Replimune’s primary value proposition is its proprietary ImmunoViroTherapy platform, which is designed to both directly lyse tumors and activate immune pathways that enhance the effectiveness of cancer immunotherapy.
The company’s lead revenue drivers are its clinical-stage product candidates, as it does not yet generate commercial product revenue. Replimune primarily serves oncology patients through collaborations with clinical investigators and pharmaceutical partners. Its strategic positioning is based on engineering large-genome herpes simplex virus type 1 (HSV-1) vectors that can deliver multiple immune-enhancing payloads, differentiating it from other oncolytic virus developers. Replimune was founded in 2015 and became publicly traded in 2018 following its initial public offering, using the proceeds to advance its pipeline through mid- and late-stage clinical development.
Business Operations
Replimune’s operations are centered on research and development across multiple clinical programs targeting solid tumors. Its core business consists of advancing proprietary oncolytic virus candidates through clinical trials, with expenses largely driven by R&D, manufacturing, and regulatory activities. The company’s most advanced programs include RP1, RP2, and RP3, which are engineered HSV-1–based therapies designed for intratumoral administration, often in combination with immune checkpoint inhibitors.
The company conducts clinical development activities in both domestic and international settings, including the United States and Europe. Replimune controls its core viral engineering technologies and maintains internal capabilities for vector design and early-stage manufacturing, while also relying on third-party contract manufacturers. Strategic collaborations with pharmaceutical companies, including checkpoint inhibitor developers, support combination trials and broaden clinical applicability.
Strategic Position & Investments
Replimune’s strategic direction is focused on advancing its lead candidate RP1 toward potential regulatory approval while expanding the clinical utility of its platform across additional tumor types and earlier lines of therapy. Growth initiatives center on late-stage clinical trials, combination strategies with approved immunotherapies, and the continued development of next-generation oncolytic virus constructs.
The company has made significant investments in its clinical pipeline rather than pursuing a broad acquisition strategy, reflecting its status as a development-stage biotechnology firm. Its portfolio includes wholly owned programs rather than externally acquired assets, and there are no material diversified investments outside its oncology focus. Replimune is also involved in emerging areas of cancer treatment that integrate innate and adaptive immune activation, positioning it within the broader immuno-oncology innovation landscape.
Geographic Footprint
Replimune is headquartered in Woburn, Massachusetts, which serves as its primary center for corporate management and research operations. The company also maintains a significant presence in the United Kingdom, reflecting its historical roots and ongoing scientific and clinical activities there.
Its clinical trial footprint spans North America and Europe, with investigational sites in multiple countries supporting patient enrollment and regulatory engagement. While Replimune does not yet have commercial operations, its international clinical development strategy is designed to support future global regulatory filings and potential market entry.
Leadership & Governance
Replimune was founded by experienced biotechnology executives with deep expertise in oncology and virology. The leadership team emphasizes scientific rigor, disciplined capital allocation, and a long-term strategy focused on building differentiated immunotherapy assets. The company is governed by a board of directors with backgrounds in biotechnology, pharmaceuticals, and public company oversight.
Key members of the leadership team include:
- Sushil Patel – Chief Executive Officer and President
- Philip Astley-Sparke – Chief Financial Officer
- Karen Ingalls – Chief Operating Officer
- Dr. Robert Coffin – Founder and Chief Scientific Officer
- Dr. Igor Splawski – Chief Medical Officer
The leadership’s strategic vision centers on establishing Replimune as a leader in oncolytic immunotherapy through successful clinical execution and potential regulatory approvals for its lead programs.